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Objectives: To provide susceptibility data for community-acquired respiratory tract isolates of Streptococcus
pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis collected in 2012–14
from four Asian countries.
Methods: MICs were determined using Etestw for all antibiotics except erythromycin, which was evaluated by disc
diffusion. Susceptibility was assessed using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) break-
points. For macrolide/clindamycin interpretation, breakpoints were adjusted for incubation in CO2 where available.
Results: Susceptibility of S. pneumoniae was generally lower in South Korea than in other countries. Penicillin sus-
ceptibility assessed using CLSI oral or EUCAST breakpoints ranged from 21.2% in South Korea to 63.8% in Singapore.
In contrast, susceptibility using CLSI intravenous breakpoints was much higher, at 79% in South Korea and95% or
higher elsewhere. Macrolide susceptibility was20% in South Korea and50%–60% elsewhere. Among S. pyogenes
isolates (India only), erythromycin susceptibility (20%) was lowest of the antibiotics tested. In H. influenzae
antibiotic susceptibility was high except for ampicillin, where susceptibility ranged from 16.7% in South Korea
to 91.1% in India. South Korea also had a high percentage (18.1%) of b-lactamase-negative ampicillin-resistant
isolates. Amoxicillin/clavulanic acid susceptibility for each pathogen (PK/PD high dose) was between 93% and
100% in all countries except for H. influenzae in South Korea (62.5%).
Conclusions: Use of EUCAST versus CLSI breakpoints had profound differences for cefaclor, cefuroxime and ofloxa-
cin, with EUCASTshowing lower susceptibility. There was considerable variability in susceptibility among countries in
the same region. Thus, continued surveillance is necessary to track future changes in antibiotic resistance.
Introduction
Community-acquired pneumonia (CAP) remains a significant
health problem. Acute respiratory infections are the cause of
death in 15% of children under the age of 5 years globally and
in 3%–12% in the four countries (India, Singapore, South Korea
and Thailand) considered here.1 CAP is also a clinical and eco-
nomic burden in the expanding ageing population.2 Resistance
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to antimicrobial agents is a worldwide phenomenon and their use
is the main driver of the emergence of resistance.3 – 5 Although
some have not observed a correlation between mortality due to
CAP and antimicrobial resistance,6 including patients in Asia,7
others found that penicillin resistance was related to increased
mortality in hospitalized patients with pneumococcal pneumo-
nia8 and that macrolide resistance in respiratory pathogens was
related to treatment failures in children.9 An Asian Network for
Surveillance of Resistant Pathogens (ANSORP) study also found
an association between mortality and levofloxacin resistance
with invasive pneumococcal disease.10
In Asia antibiotic resistance in CAP is generally high, as demon-
strated by data from the ANSORP 2008–09 and the Community-
Acquired Respiratory Tract Infection Pathogen Surveillance
(CARTIPS) study (2009–10).10,11 Korea also showed high multidrug
resistance rates in S. pneumoniae, particularly those strains non-
susceptible to levofloxacin.12 Data from India are limited, but
another study showed slightly lower non-susceptibility to penicillin
in S. pneumoniae than that observed in ANSORP,11 at 14%, but with
similar susceptibility to erythromycin.13 In Korea ampicillin resist-
ance was high (59%) in Haemophilus influenzae, as was resistance
to clarithromycin (19%) and amoxicillin/clavulanic acid (10%).14
CAP is usually treated empirically, without identification and
susceptibility testing of the causative agent, and knowledge of
local resistance patterns is therefore especially important when
treating this disease. Additionally, surveillance data can provide
useful information to assist governments in controlling antimicro-
bial use and emergence of resistance.
The Survey of Antibiotic Resistance (SOAR) is an ongoing sur-
veillance study of key respiratory pathogens. SOAR has been mon-
itoring antimicrobial resistance in the Middle East, Africa, Latin
America, Asia-Pacific and the Commonwealth of Independent
States countries since 2002. We present an analysis of recent
data from four Asian countries to provide a picture of the current
antimicrobial susceptibility situation in four community-acquired
respiratory tract infection (CA-RTI) pathogens, Streptococcus
pneumoniae, Streptococcus pyogenes, H. influenzae and Moraxella
catarrhalis.
Materials and methods
Collaborating centres
Isolates were collected from eight sites in South Korea (Daejoen St Mary’s
Hospital; Ilsan Hospital; Incheon St Mary’s Hospital; Myongji Hospital;
Seoul St Mary’s Hospital; Severance Hospital; Uijeongbu St Mary’s
Hospital; and St Vincent’s Hospital), four sites in India (Choithram
Hospital, Indore; Christian Medical College & Hospital; Vellore, P.D.
Hinduja National Hospital & Medical Research Center; and St John’s
Medical College), four sites in Thailand (Maharaj Nakorn Chiang Mai
Hospital; Hat-Yai Hospital; Ramathibodi Hospital; and Srinagarind
Hospital) and one site in Singapore (Changi General Hospital).
Clinical isolates
During 2012–14, a total of 1326 clinical respiratory isolates (520 from
Thailand, 493 from India, 175 from South Korea and 138 from
Singapore), comprising 570 isolates of S. pneumoniae, 78 isolates of S. pyo-
genes (India only), 148 isolates of M. catarrhalis and 530 isolates of H. influ-
enzae, were analysed.
All patients were from the community (hospitals and university hospi-
tals). Paediatric patients (≤12 years old) accounted for 220 isolates
(16.6%), adult patients (13–64 years old) for 696 (52.5%) and the elderly
(≥65 years) for 410 isolates (30.9%). All of the S. pyogenes isolates were
from throat swabs and the other pathogens were obtained from a variety
of specimen types, including blood, bronchoalveolar lavage, middle ear
effusion, nasopharyngeal aspirate, pleural fluid, sinus, sputum and tra-
cheal aspirate. Organisms were identified using conventional methods
(optochin susceptibility/bile solubility for S. pneumoniae, X and V factor
requirement for H. influenzae, bacitracin susceptibility for S. pyogenes
and tributyrin test for M. catarrhalis). Duplicate isolates from the same
patient were excluded.
Susceptibility testing
MICs were determined by gradient strip (Etestw) according to the manufac-
turer’s instructions (bioMe´rieux, Marcy l’E´toile, France), including: amoxicillin/
clavulanic acid, azithromycin, cefaclor, cefixime, cefotaxime, cefpodoxime,
cefuroxime, clarithromycin, clindamycin, erythromycin, levofloxacin, moxi-
floxacin, ofloxacin, penicillin and trimethoprim/sulfamethoxazole against S.
pneumoniae and amoxicillin/clavulanic acid, azithromycin, cefixime, cef-
podoxime, cefuroxime, clarithromycin, erythromycin, levofloxacin, ofloxacin,
penicillin and trimethoprim/sulfamethoxazole against S. pyogenes (India
only). In addition, for these two organisms erythromycin was tested by CLSI
disc diffusion methodology.15 For H. influenzae and M. catarrhalis, amoxicillin/
clavulanic acid, ampicillin (H. influenzae only), azithromycin, cefaclor, cefixime,
cefpodoxime, cefuroxime, ciprofloxacin, clarithromycin, levofloxacin, moxi-
floxacin, ofloxacin (H. influenzae only) and trimethoprim/sulfamethoxazole
(H. influenzae only) were tested. Although not all antimicrobial agents were
tested in each country, there was substantial overlap among countries in
the panel of antimicrobial agents tested. The particular agents tested in
each country can be found in the respective summary tables of MIC data
(Tables 1–9). Quality control strains for MIC determination included S. pneu-
moniae ATCC 49619, H. influenzae ATCC 49247, H. influenzae ATCC 49766
and Escherichia coli ATCC 32518, which were tested concurrently with the clin-
ical isolates. Acceptable MIC ranges were those of CLSI16 or those provided by
the Etestwmanufacturer (bioMe´rieux, Marcy l’E´toile, France) for adjustment in
CO2. In H. influenzae and M. catarrhalis, production of b-lactamase was
assessed using a nitrocefin disc according to the manufacturer’s instructions
(BD Diagnostics, Sparks, MD, USA), with E. coli ATCC 35218 and H. influenzae
ATCC 49247 as the positive and negative controls, respectively.
The principal MIC susceptibility criteria utilized were those of CLSI,16
with the exception of the macrolides and clindamycin, for which
bioMe´rieux Etestw breakpoints for incubation at elevated CO2 tension
were used. In addition, susceptibility based on the EUCAST criteria17 and
on pharmacokinetic/pharmacodynamic (PK/PD) breakpoints18 was
assessed. These additional breakpoints were not evaluated for macrolides
(except erythromycin MIC by EUCAST) because susceptibility criteria for
Etestw incubation in elevated CO2 are available only relative to the CLSI
breakpoints. Both CLSI and EUCAST disc diffusion criteria are available
for erythromycin. The breakpoints for all three methods of evaluation
are shown in Table 1.
Statistical analysis
Differences in susceptibility between countries and age groups were
assessed with Fisher’s exact test using XLSTAT version 2011.1.05. A P
value ,0.05 was considered statistically significant. Between-country
comparisons were made for species where antibiotics were tested by at
least three countries against at least 20 isolates per country.
Results
Sources of isolates from all sites combined
Of the 570 S. pneumoniae isolates, 345 were from sputum (60.5%),
125 from blood (21.9%), 57 from tracheal aspirate (10%) and the
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Table 1. MIC breakpoints (mg/L) used for S. pneumoniae, S. pyogenes, H. influenzae and M. catarrhalis isolates
S. pneumoniae S. pyogenes H. influenzae M. catarrhalis
All
species
CLSI EUCAST CLSI EUCAST CLSI EUCAST CLSI EUCAST
PK/PD
Antimicrobial S I R S I R S I R S I R S I R S I R S I R S I R (S only)
AMCa ≤2 4 ≥8 NA NA NA NA NA NA NA NA NA ≤4 — ≥8 ≤2 — ≥4 ≤4 — ≥8 ≤1 — ≥2 ≤2 (≤4)
Ampicillin NT NT NT NT NT NT NT NT NT NT NT NT ≤1 2 ≥4 ≤1 — ≥2 NT NT NT NT NT NT NA
Azithromycinb ≤4 8 ≥16 NA NA NA NA NA NA NA NA NA ≤8 — —b NA NA NA NA NA NA NA NA NA NA
Cefaclor ≤1 2 ≥4 ≤0.03 0.06–0.5 ≥1 NT NT NT NT NT NT ≤8 16 ≥32 NA NA NA ≤8 16 ≥32 NA NA NA ≤0.5
Cefixime NA NA NA NA NA NA NA NA NA NA NA NA ≤1 — — ≤0.12 — ≥0.25 NA NA NA ≤0.5 1 ≥2 ≤1
Cefotaxime ≤1 2 ≥4 ≤0.5 1–2 ≥4 NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NA
Cefpodoxime ≤0.5 1 ≥2 ≤0.25 0.5 ≥1 NA NA NA NA NA NA ≤2 — — ≤0.25 0.5 ≥0.1 NA NA NA NA NA NA ≤0.5
Cefuroximec ≤1 2 ≥4 ≤0.25 0.5 ≥1 NA NA NA NA NA NA ≤4 8 ≥16 ≤0.12 0.25–1 ≥2 ≤4 8 ≥16 ≤0.12 0.25–4 ≥8 ≤1
Ciprofloxacin NT NT NT NT NT NT NT NT NT NT NT NT ≤1 — — ≤0.5 — ≥1 ≤1 — — ≤0.5 — ≥1 ≤1
Clarithromycinb ≤0.5 1 ≥2 NA NA NA NA NA NA NA NA NA ≤16 32 ≥64 NA NA NA NA NA NA NA NA NA NA
Clindamycinb ≤0.5 1 ≥2 NA NA NA NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NA
Erythromycinb ≤1 2 ≥4 ≤1 2 ≥4 ≤1 2 ≥4 NA NA NA NT NT NT NT NT NT NT NT NT NT NT NT NA
Levofloxacin ≤2 4 ≥8 ≤2 — ≥4 ≤2 4 ≥8 ≤1 2 ≥4 ≤2 — — ≤1 — ≥2 ≤2 — — ≤1 — ≥2 ≤2
Moxifloxacin ≤1 2 ≥4 ≤0.5 — ≥1 NT NT NT NT NT NT ≤1 — — ≤0.5 — ≥1 NA NA NA ≤0.5 — ≥1 ≤1
Ofloxacin ≤2 4 ≥8 ≤0.12 0.25–4 ≥8 ≤2 4 ≥8 NA NA NA ≤2 — — ≤0.5 — ≥1 NT NT NT NT NT NT NA
Penicillin (oral) ≤0.06 0.12–1 ≥2 ≤0.06 0.12–2 ≥4 ≤0.12 — — ≤0.25 — ≥0.5 NT NT NT NT NT NT NT NT NT NT NT NT NA
Penicillin (iv)d ≤2 4 ≥8 NA NA NA NA NA NA NA NA NA NT NT NT NT NT NT NT NT NT NT NT NT NA
SXTe ≤0.5 1–2 ≥4 2 ≥4 NA NA ≤1 2 ≥4 ≤0.5 1–2 ≥4 ≤0.5 1 ≥2 NT NT NT NT NT NT ≤0.5
AMC, amoxicillin/clavulanic acid; S, susceptible; I, intermediate; R, resistant; NA, not applicable; NT, not tested; SXT, trimethoprim/sulfamethoxazole.
aThis agent was tested at a 2:1 amoxicillin to clavulanic acid ratio; breakpoints are expressed as the amoxicillin component. PK/PD breakpoint based on high-dose (4 g of amoxicillin with
250 mg of clavulanic acid per day for adults) is shown in parentheses.
bbioMe´rieux Etestw breakpoints for incubation in CO2.
cBreakpoints used are for cefuroxime axetil.
dParenteral non-meningitis breakpoints. EUCAST does not indicate iv breakpoints but dose-specific susceptible breakpoints are noted for pneumonia: 1.2 g×4 (MIC≤0.5 mg/L¼ susceptible),
1.2 g×6 or 2.4 g×4 (MIC ≤1 mg/L¼susceptible) and 2.4 g×6 (MIC ≤2 mg/L¼ susceptible).
eTrimethoprim/sulfamethoxazole was tested at a 1:19 ratio.
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Table 2. MIC and susceptibility results for S. pneumoniae isolates by country
Susceptibility
MIC (mg/L) CLSI PK/PD EUCAST
Antimicrobial na 50% 90% min max %S %I %R %S %S %I %R
India
AMCb,c 219 0.06 2 ≤0.015 .256 91.8 2.7 5.5 91.8 (94.5) NA NA NA
azithromycind 199 1 .256 ≤0.015 .256 66.3 13.6 20.1 NA NA NA NA
cefixime 219 2 32 ≤0.015 .256 NA NA NA 49.8 NA NA NA
cefpodoxime 219 0.25 4 ≤0.015 .256 67.1 9.1 23.7 67.1 55.3 11.9 32.9
cefuroximee 218 0.25 4 ≤0.015 .256 75.2 8.7 16.1 75.2 51.4 13.8 34.9
clarithromycind 199 0.25 .256 ≤0.015 .256 54.8 2.0 43.2 NA NA NA NA
erythromycind 183 0.25 .256 ≤0.015 .256 57.4 8.2 34.4 NA 57.4 8.2 34.4
levofloxacin 219 1 .32 0.12 .32 85.8 3.2 11.0 85.8 85.8 0.0 14.2
ofloxacin 219 2 .32 0.5 .32 77.2 9.1 13.7 NA 0.0 86.3 13.7
penicillin (oral) 219 0.12 2 ≤0.015 .32 49.3 33.8 16.9 NA 49.3 46.1 4.6
penicillin (iv) 219 0.12 2 ≤0.015 .32 95.4 2.7 1.8 NA 73.5–95.4 NA NA
SXT 219 1 16 ≤0.015 .32 32.9 39.3 27.9 32.9 55.3 16.9 27.8
erythromycinf 218 — — — — 49.1 12.8 38.1 — 49.1 4.6 46.3
South Korea
AMCb,c 85 1 4 ≤0.015 8 81.2 16.5 2.4 81.2 (97.6) NA NA NA
azithromycind 85 .256 .256 0.12 .256 20.0 1.2 78.8 NA NA NA NA
cefaclor 85 32 .256 0.12 .256 24.7 3.5 71.8 23.5 0.0 23.5 76.5
cefotaxime 85 0.5 2 ≤0.015 32 85.9 5.9 8.2 NA 50.6 41.2 8.2
cefuroximee 85 2 8 ≤0.015 .256 36.5 18.8 44.7 36.5 29.4 0.0 70.6
clarithromycind 85 .256 .256 0.06 .256 18.8 0.0 81.2 NA NA NA NA
clindamycind 85 .256 .256 ≤0.015 .256 31.8 1.2 67.1 NA NA NA NA
levofloxacin 85 1 2 0.25 .32 91.8 0.0 8.2 91.8 91.8 0.0 8.2
ofloxacin 85 2 4 1 .32 75.3 16.5 8.2 NA 0.0 91.8 8.2
penicillin (oral) 85 1 4 ≤0.015 16 21.2 35.3 43.5 NA 21.2 57.6 21.2
penicillin (iv) 85 1 4 ≤0.015 16 78.8 17.7 3.5 NA 37.6–78.8 NA NA
SXT 85 1 .32 0.12 .32 43.5 11.8 44.7 43.5 54.1 1.2 44.7
erythromycinf 85 — — — — 18.8 0.0 81.2 — 17.6 1.2 81.2
Singapore
AMCb,c 58 0.03 2 ≤0.015 4 94.8 5.2 0.0 94.8 (100) NA NA NA
azithromycind 58 2 .256 0.25 .256 56.9 5.2 37.9 NA NA NA NA
cefaclor 58 1 .256 0.5 .256 67.2 5.2 27.6 19.0 0.0 19.0 81.0
cefuroximee 58 0.06 4 ≤0.015 32 79.3 3.5 17.2 79.3 72.4 3.5 24.1
clarithromycind 58 0.25 .256 0.06 .256 56.9 0.0 43.1 NA NA NA NA
levofloxacin 58 1 2 0.5 4 98.3 1.7 0.0 98.3 98.3 0.0 1.7
moxifloxacin 58 0.12 0.25 0.06 0.25 100 0.0 0.0 100 100 0.0 0.0
ofloxacin 58 4 4 0.06 8 43.1 53.5 3.5 NA 1.7 94.8 3.5
penicillin (oral) 58 0.03 2 ≤0.015 4 63.8 25.9 10.3 NA 63.8 31.0 5.2
penicillin (iv) 58 0.03 2 ≤0.015 4 94.8 5.2 0.0 NA 81.0–94.8 NA NA
SXT 58 1 .32 0.12 .32 43.1 10.3 46.6 43.1 50.0 3.5 46.6
erythromycinf 58 — — — — 55.2 1.7 43.1 — 55.2 0.0 44.8
Thailand
AMCb,c 208 0.06 1 ≤0.015 32 97.1 1.9 1.0 97.1 (99.0) NA NA NA
azithromycind 208 2 .256 0.03 .256 53.4 1.0 45.7 NA NA NA NA
cefuroximee 208 0.12 2 ≤0.015 32 77.9 16.3 5.8 77.9 59.1 7.2 33.7
clarithromycind 208 0.25 .256 0.03 .256 52.4 0.0 47.6 NA NA NA NA
levofloxacin 208 1 2 0.5 16 98.1 1.4 0.5 98.1 98.1 0.0 1.9
penicillin (oral) 208 0.12 1 ≤0.015 8 49.0 46.2 4.8 NA 49.0 49.0 1.9
Continued
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remainder from bronchoalveolar lavage, bronchial aspirate, sinus,
middle ear effusion, nasopharyngeal aspirate or pleural fluid.
Most isolates were from adults (n¼303, 53.2%) with 191 isolates
from elderly (33.5%) and 76 from paediatric patients (13.3%).
All 78 S. pyogenes isolates were from throat swabs and all were
collected in India. The majority were from paediatric patients
(n¼46, 59.0%); 32 isolates (41.0%) were from adult patients
and there were none from elderly patients.
The majority of the 530 H. influenzae isolates came from spu-
tum (n¼386, 72.8%); 38 isolates were from sinus or tracheal aspi-
rates (7.2% each), 37 (7.0%) were from bronchoalveolar lavage and
21 (4.0%) were from blood. The remainder were from middle ear
effusions, nasopharyngeal aspirate or bronchial aspirate. Adults
accounted for 290 isolates (54.7%), elderly patients for 166 isolates
(31.3%) and paediatric patients for 74 isolates (14.0%).
For M. catarrhalis, the vast majority of the 148 isolates were
from sputum (n¼111, 75.0%), with 17 isolates from tracheal
aspirate (11.5%) and the remainder from sinus, bronchoalveolar
lavage, nasopharyngeal aspirate and blood. Adults accounted
for 71 isolates (48.0%), elderly patients for 53 isolates (35.8%)
and paediatric patients for 24 isolates (16.2%). All isolates from
Singapore and Thailand were b-lactamase positive, as were
83.3% and 72.1% from South Korea and India, respectively.
S. pneumoniae susceptibility in individual countries
Summary MIC and susceptibility data for S. pneumoniae isolates
for each individual country are shown in Table 2 and MIC distribu-
tion data are shown in Table 3.
India
Using the CLSI iv breakpoint, 95.4% of the isolates from India were
susceptible to penicillin (PSSP), whereas only 49.3% were PSSP
according to the CLSI oral and the EUCAST criteria. With these
two breakpoints, 33.8% and 46.1% were scored as penicillin inter-
mediate (PISP), respectively, and 16.9% and 4.6% of isolates were
penicillin resistant (PRSP), respectively (Table 2).
Only amoxicillin/clavulanic acid (or amoxicillin alone as inferred
from the amoxicillin/clavulanic acid data) had .90% susceptibility
by both CLSI and PK/PD criteria; 94.5% of isolates were susceptible
to high-dose amoxicillin/clavulanic acid (PK/PD) (Table 2).
The fluoroquinolones were more active, with 85.8% of isolates
susceptible to levofloxacin (by all three breakpoint criteria) and
77.2% susceptible to ofloxacin by CLSI breakpoints. EUCAST
breakpoints, on the other hand, considered all S. pneumoniae to
be non-susceptible to ofloxacin (Table 2).
Of the three macrolides tested, azithromycin had the highest
activity (CLSI breakpoints in CO2), at 66.3% susceptible, and cla-
rithromycin and erythromycin had lower activity, at 54.8% and
57.4%, respectively (CLSI breakpoints in CO2). By disc, erythromy-
cin susceptibility was 49.1% according to both CLSI and EUCAST
breakpoints (Table 2).
South Korea
Using the CLSI iv breakpoint, 78.8% of isolates were PSSP, whereas
only 21.2% were PSSP according to both the CLSI oral and the
EUCAST criteria. With these two breakpoints, 35.3% and 57.6%,
respectively, were scored as PISP and 43.5% and 21.2%, respect-
ively, were PRSP (Table 2).
Only for levofloxacin was there .90% susceptibility by CLSI or
EUCAST breakpoints (91.8%), although amoxicillin/clavulanic acid
had 97.6% susceptibility according to high-dose PK/PD break-
points and 81.2% susceptibility by CLSI breakpoints. Cefotaxime
susceptibility was also high by CLSI breakpoints (85.9%), but
this dropped to 50.6% susceptible by EUCAST breakpoints. Other
cephalosporins, cefaclor and cefuroxime, were less active, at
24.7% and 36.5% susceptible by CLSI breakpoints, respectively.
According to EUCAST breakpoints, susceptibility to the two cepha-
losporins was 0% and 29.4%, respectively (Table 2).
Susceptibility to macrolides in South Korea was very low, at
around 20% (CLSI breakpoints in CO2), which was confirmed by
disc diffusion for erythromycin according to both CLSI and
EUCAST breakpoints.
Singapore
Using the CLSI iv breakpoint, 94.8% of strains were PSSP. With the
CLSI oral and EUCAST breakpoints, 63.8% and 63.8% of isolates
Table 2. Continued
Susceptibility
MIC (mg/L) CLSI PK/PD EUCAST
Antimicrobial na 50% 90% min max %S %I %R %S %S %I %R
penicillin (iv) 208 0.12 1 ≤0.015 8 98.1 1.0 1.0 NA 84.1–98.1 NA NA
erythromycinf 208 — — — — 51.9 1.9 46.2 NA 51.9 0.0 48.1
min, minimum; max, maximum; S, susceptible; I, intermediate; R, resistant; AMC, amoxicillin/clavulanic acid; NA, no breakpoint data available (NA for
azithromycin, clindamycin and clarithromycin by EUCAST or PK/PD because Etestw breakpoints in CO2 not available); SXT, trimethoprim/sulfamethoxazole.
aNot all isolates were tested. Although amoxicillin has not been tested against S. pneumoniae, percentage susceptibility to amoxicillin and amoxicillin/
clavulanic acid is expected to be the same.
bPK/PD susceptibility at high dose is shown in parentheses.
cFor S. pneumoniae susceptibility to amoxicillin alone can be inferred from amoxicillin/clavulanic acid data.
dbioMe´rieux Etestw breakpoints for incubation in CO2.
eBreakpoints used are for cefuroxime axetil.
fUsing S/I/R zone diameters (mm) of CLSI (≤15/16–20/≥21) and EUCAST (≤18/19–21/≥22).
SOAR: Thailand, India, South Korea and Singapore 2012–14
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were PSSP, respectively; 25.9% and 31.0% were PISP and 10.3%
and 5.2% were PRSP (Table 2).
Susceptibility to amoxicillin/clavulanic acid (amoxicillin) was
94.8% according to CLSI breakpoints and low-dose PK/PD break-
points, but all isolates were susceptible at the high-dose PK/PD
breakpoint. Similarly, all isolates were susceptible to moxifloxacin
and 98.3% of isolates susceptible to levofloxacin (by all three
breakpoints). Ofloxacin susceptibility was much lower, at 43.1%
by CLSI and 1.7% by EUCAST.
Among cephalosporins, cefuroxime showed 79.3% sus-
ceptibility by both CLSI and PK/PD breakpoints and 72.4% by
EUCAST breakpoints. Cefaclor susceptibility was 0% by EUCAST
Table 3. Distribution of S. pneumoniae MICs by country
Number of isolates at MIC (mg/L)
Antimicrobial na ≤0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 .32 64 128 256 .256
India
AMC 219 59 43 12 20 12 13 21 21 6 4 3 2 0 0 1 0 2
azithromycin 199 2 1 4 10 11 31 46 15 12 27 8 3 0 1 1 0 27
cefixime 219 1 0 3 16 32 37 20 23 24 12 15 22 0 5 1 0 8
cefpodoxime 219 15 44 29 17 16 26 20 22 17 8 2 0 0 1 0 0 2
cefuroxime 218 22 53 8 12 17 30 22 19 16 11 4 1 0 1 0 0 2
clarithromycin 199 1 8 23 54 22 1 4 19 29 8 3 4 0 0 0 0 23
erythromycin 183 5 13 21 47 18 0 1 15 21 13 0 4 0 0 0 1 24
levofloxacin 219 0 0 0 1 2 27 116 42 7 1 0 0 23 0 0 0 0
ofloxacin 219 0 0 0 0 0 4 41 124 20 6 1 0 23 0 0 0 0
penicillin 219 36 56 16 22 16 15 21 27 6 0 3 0 1 0 0 0 0
SXT 219 1 5 8 16 18 24 49 37 15 21 9 1 15 0 0 0 0
South Korea
AMC 85 16 1 3 2 4 11 13 19 14 2 0 0 0 0 0 0 0
azithromycin 85 0 0 0 2 5 9 1 0 0 1 4 4 0 1 0 0 58
cefaclor 85 0 0 0 6 9 5 1 3 1 2 14 12 0 13 6 3 10
cefotaxime 85 14 0 1 7 3 18 30 5 1 5 0 1 0 0 0 0 0
cefuroxime 85 14 0 0 4 7 0 6 16 25 7 4 0 0 1 0 0 1
clarithromycin 85 0 0 2 9 5 0 0 0 1 6 2 1 0 1 0 1 57
clindamycin 85 1 0 2 10 13 1 1 0 0 0 0 0 0 0 0 0 57
levofloxacin 85 0 0 0 0 1 9 63 5 0 0 0 0 7 0 0 0 0
ofloxacin 85 0 0 0 0 0 0 1 63 14 0 0 0 7 0 0 0 0
penicillin 85 11 5 2 2 5 7 16 19 15 1 2 0 0 0 0 0 0
SXT 85 0 0 0 18 16 3 9 1 9 7 3 2 17 0 0 0 0
Singapore
AMC 58 5 32 1 1 5 2 3 6 3 0 0 0 0 0 0 0 0
azithromycin 58 0 0 0 0 2 6 13 12 0 3 2 2 0 1 1 0 16
cefaclor 58 0 0 0 0 0 11 28 3 2 1 2 1 0 1 0 1 8
cefuroxime 58 0 20 9 3 7 2 2 2 7 1 1 1 0 0 0 0 0
clarithromycin 58 0 0 6 18 9 0 0 2 3 2 1 0 0 2 0 0 15
levofloxacin 58 0 0 0 0 0 2 48 7 1 0 0 0 0 0 0 0 0
moxifloxacin 58 0 0 1 43 14 0 0 0 0 0 0 0 0 0 0 0 0
ofloxacin 58 0 0 1 0 0 0 0 24 31 2 0 0 0 0 0 0 0
penicillin 58 15 18 4 2 6 2 5 3 3 0 0 0 0 0 0 0 0
SXT 58 0 0 0 2 20 3 4 2 3 10 5 0 9 0 0 0 0
Thailand
AMC 208 63 31 14 13 14 37 23 7 4 0 1 1 0 0 0 0 0
azithromycin 208 0 1 0 4 15 16 63 8 4 2 7 25 0 5 0 1 57
cefuroxime 208 63 21 10 12 17 15 24 34 10 1 0 1 0 0 0 0 0
clarithromycin 208 0 4 17 75 12 1 0 0 18 21 6 3 0 0 0 0 51
levofloxacin 208 0 0 0 0 0 29 142 33 3 0 1 0 0 0 0 0 0
penicillin 208 71 18 13 15 20 38 23 6 2 2 0 0 0 0 0 0 0
AMC, amoxicillin/clavulanic acid (2:1); SXT, trimethoprim/sulfamethoxazole (1:19).
aNot all isolates were tested.
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breakpoints (as shown in South Korea), 19.0% by PK/PD criteria
and 67.2% by CLSI. Azithromycin susceptibility was 56.9% (CLSI
breakpoints in CO2) and erythromycin susceptibility by CLSI or
EUCAST disc diffusion was 55.2% (Table 2).
Thailand
Using the CLSI iv breakpoint, 98.1% of isolates were PSSP (1.0%
PISP, 1.0% PRSP), but only 49.0% of the isolates were PSSP by
CLSI oral and EUCASTcriteria (46.2% and 49.0% PISP, respectively;
4.8% and 1.9% PRSP). Susceptibility to amoxicillin/clavulanic acid
(amoxicillin) was 97.1% by CLSI or low-dose PK/PD breakpoints
and 99.0% by high-dose PK/PD. Levofloxacin susceptibility was
also high, at 98.1% (by all three breakpoint criteria). Cefuroxime
was the only cephalosporin tested; 77.9% of strains were suscep-
tible by CLSI and PK/PD breakpoints and 59.1% by EUCAST. Among
macrolides, around 50% of isolates were susceptible to azithro-
mycin and clarithromycin using CLSI breakpoints in CO2 or to
Table 4. MIC and susceptibility results for S. pyogenes (India only)
Susceptibility
MIC (mg/L) CLSI PK/PD EUCAST
Antimicrobial n 50% 90% min max %S %I %R %S %S %I %R
India
AMCa 78 0.03 0.25 ≤0.015 1 100b 0.0 0.0 100 (100) 100b 0.0 0.0
azithromycin 78 64 .256 0.12 .256 NA NA NA NA NA NA NA
cefixime 78 0.25 0.5 0.03 32 100b 0.0 0.0 98.7 100b 0.0 0.0
cefpodoxime 78 0.03 0.03 ≤0.015 4 100b 0.0 0.0 98.7 100b 0.0 0.0
cefuroxime 78 ≤0.015 0.03 ≤0.015 1 100b 0.0 0.0 100 100b 0.0 0.0
clarithromycin 78 32 .256 0.06 .256 NA NA NA NA NA NA NA
erythromycinc 76 16 .256 0.06 .256 23.7 7.9 68.4 NA NA NA NA
levofloxacin 78 1 .32 0.5 .32 79.5 9.0 11.5 79.5 55.1 24.4 20.5
ofloxacin 78 2 .32 1 .32 52.6 24.4 23.1 NA NA NA NA
penicillin 78 0.015 0.03 ≤0.015 0.12 100 0.0 0.0 NA 100 0.0 0.0
SXT 78 .32 .32 ≤0.015 .32 NA NA NA 33.3 33.3 0.0 66.7
erythromycind 78 — — — — 21.8 7.7 70.5 — 21.8 3.8 74.4
min, minimum; max, maximum; S, susceptible; I, intermediate; AMC, amoxicillin/clavulanic acid; NA, no breakpoint data available (NA for macrolides by
EUCAST or PK/PD because Etestw breakpoints in CO2 not available); SXT, trimethoprim/sulfamethoxazole.
aPK/PD susceptibility at high dose is shown in parentheses.
bCLSI and EUCAST guidelines assumes susceptibility to amoxicillin/clavulanic acid and cephalosporins based on penicillin susceptibility.
cbioMe´rieux Etestw breakpoints for incubation in CO2.
dUsing S/I/R zone diameters (mm) of CLSI (≤15/16–20/≥21) and EUCAST (≤18/19–21/≥22).
Table 5. Distribution of S. pyogenes MICs (India only)
Number of isolates at MIC (mg/L)
Antimicrobial n ≤0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 .32 64 128 256 .256
India
AMC 78 23 38 6 3 2 4 2 0 0 0 0 0 0 0 0 0 0
azithromycin 78 0 0 0 1 0 3 12 7 2 1 6 6 0 14 6 6 14
cefixime 78 0 1 7 17 44 7 1 0 0 0 0 1 0 0 0 0 0
cefpodoxime 78 23 52 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0
cefuroxime 78 43 32 2 0 0 0 1 0 0 0 0 0 0 0 0 0 0
clarithromycin 78 0 0 4 8 9 0 2 3 2 1 9 18 0 8 0 0 14
erythromycin 76 0 0 1 10 7 0 0 6 4 3 11 17 0 4 0 0 13
levofloxacin 78 0 0 0 0 0 24 19 19 7 1 0 0 8 0 0 0 0
ofloxacin 78 0 0 0 0 0 0 20 21 19 5 3 0 10 0 0 0 0
penicillin 78 42 34 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0
SXT 78 1 3 8 5 1 8 0 0 0 0 0 0 52 0 0 0 0
AMC, amoxicillin/clavulanic acid (2:1); SXT, trimethoprim/sulfamethoxazole (1:19).
SOAR: Thailand, India, South Korea and Singapore 2012–14
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Table 6. MIC and susceptibility results for H. influenzae isolates by country
Susceptibility
MIC (mg/L) CLSI PK/PD EUCAST
Antimicrobial Isolate group n 50% 90% min max %S %I %R %S %S %I %R
India
AMCa,b All 135 0.5 4 ≤0.015 .256 97.0 0.0 3.0 89.6 (97.0) 89.6 0.0 10.4
BL2 124 0.5 2 ≤0.015 8 99.2 0.0 0.8 91.9 (99.2) 91.9 0.0 8.1
BL+ 11 2 .256 0.03 .256 72.7 0.0 27.3 63.6 (72.7) 63.6 0.0 36.4
ampicillinc All 135 0.25 1 ≤0.015 32 91.1 1.5 7.4 NA 91.1 0.0 8.9
BL2 124 0.25 0.5 ≤0.015 2 99.2 0.8 0.0 NA 99.2 0.0 0.8
BL+ 11 4 16 2 32 0.0 9.1 90.9 NA 0.0 0.0 100
azithromycind All 94 4 8 ≤0.015 .256 94.7 0.0 5.3 NA NA NA NA
BL2 87 4 8 ≤0.015 .256 94.3 0.0 5.8 NA NA NA NA
BL+ 7 4 8 ≤0.015 8 100 0.0 0.0 NA NA NA NA
cefixime All 135 0.06 0.5 ≤0.015 .256 97.0 0.0 3.0 97.0 85.2 0.0 14.8
BL2 124 0.06 0.5 ≤0.015 .256 96.8 0.0 3.2 96.8 84.7 0.0 15.3
BL+ 11 0.03 0.12 ≤0.015 0.5 100 0.0 0.0 100 90.9 0.0 9.1
cefpodoxime All 134 0.06 1 ≤0.015 .256 97.0 0.0 3.0 89.5 78.4 11.2 10.5
BL2 123 0.12 1 ≤0.015 .256 96.7 0.0 3.3 88.6 78.1 10.6 11.4
BL+ 11 0.06 0.5 0.03 0.5 100 0.0 0.0 100 81.8 18.2 0.0
cefuroximee,b All 134 0.5 1 ≤0.015 .256 99.3 0.0 0.8 90.3 17.9 72.4 9.7
BL2 123 0.5 1 ≤0.015 .256 99.2 0.0 0.8 91.9 18.7 73.2 8.1
BL+ 11 1 2 ≤0.015 4 100 0.0 0.0 72.7 9.1 63.6 27.3
ciprofloxacin All 135 0.5 8 ≤0.015 .32 76.3 0.0 23.7 76.3 59.3 0.0 40.7
BL2 124 0.5 8 ≤0.015 .32 75.0 0.0 25.0 75.0 58.1 0.0 41.9
BL+ 11 0.25 1 ≤0.015 8 90.9 0.0 9.1 90.9 72.7 0.0 27.3
clarithromycind All 108 16 64 0.06 .256 66.7 19.4 13.9 NA NA NA NA
BL2 99 16 64 0.06 .256 65.7 19.2 15.2 NA NA NA NA
BL+ 9 8 32 1 32 77.8 22.2 0.0 NA NA NA NA
levofloxacin All 135 0.5 8 ≤0.015 .32 85.2 0.0 14.8 85.2 79.3 0.0 20.7
BL2 124 0.5 8 ≤0.015 .32 84.7 0.0 15.3 84.7 78.2 0.0 21.8
BL+ 11 0.5 1 0.03 8 90.9 0.0 9.1 90.9 90.9 0.0 9.1
ofloxacin All 135 0.5 8 ≤0.015 .32 80.7 0.0 19.3 NA 53.3 0.0 46.7
BL2 124 0.5 .32 ≤0.015 .32 79.8 0.0 20.2 NA 51.6 0.0 48.4
BL+ 11 0.5 2 0.06 8 90.9 0.0 9.1 NA 72.7 0.0 27.3
SXT All 135 4 .32 ≤0.015 .32 23.0 13.3 63.7 23.0 23.0 5.2 71.9
BL2 124 4 .32 ≤0.015 .32 25.0 13.7 61.3 25.0 25.0 4.8 70.2
BL+ 11 .32 .32 1 .32 0.0 9.1 90.9 0 0.0 9.1 90.9
South Korea
AMCa,b All 72 4 32 0.25 .256 62.5 (56.9)f 0.0 0.0 37.5 (43.1)f 38.9 (62.5) 38.9 (31.9)f 0.0 61.1 (68.1)f
BL2 30 4 16 0.25 .256 66.7 0.0 33.3 36.7 (66.7) 36.7 0.0 63.3
BL+ 42 4 32 0.5 .256 59.5 0.0 40.5 40.5 (59.5) 40.5 0.0 59.5
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ampicillinc All 72 64 .256 0.25 .256 16.7 13.9 69.4 NA 16.7 0.0 83.3
BL2 30 2 16 0.25 .256 26.7 30.0 43.3 NA 26.7 0.0 73.3
BL+ 42 .256 .256 0.25 .256 9.5 2.4 88.1 NA 9.5 0.0 90.5
azithromycind All 72 2 8 0.5 .256 94.4 0.0 5.6 NA NA NA NA
BL2 30 2 8 1 .256 93.3 0.0 6.7 NA NA NA NA
BL+ 42 2 4 0.5 64 95.2 0.0 4.8 NA NA NA NA
cefaclorb All 72 64 .256 0.5 .256 29.2 (27.8)f 8.3 62.5 (63.9)f 1.4 NA NA NA
BL2 30 32 .256 0.5 .256 30.0 13.3 56.7 3.3 NA NA NA
BL+ 42 64 .256 2 .256 28.6 4.8 66.7 0 NA NA NA
cefuroximee,b All 72 16 .256 0.5 .256 40.3 (37.5)f 4.2 55.6 (58.3)f 16.7 0.0 16.7 83.3
BL2 30 4 .256 0.5 .256 50.0 6.7 43.3 16.7 0.0 16.7 83.3
BL+ 42 32 .256 0.5 .256 33.3 2.4 64.3 16.7 0.0 16.7 83.3
clarithromycind All 72 16 64 4 .256 50.0 37.5 12.5 NA NA NA NA
BL2 30 16 64 8 64 53.3 33.3 13.3 NA NA NA NA
BL+ 42 32 64 4 .256 47.6 40.5 11.9 NA NA NA NA
levofloxacin All 72 0.015 0.03 ≤0.015 1 100 0.0 0.0 100 100 0.0 0.0
BL2 30 0.015 0.03 ≤0.015 1 100 0.0 0.0 100 100 0.0 0.0
BL+ 42 0.015 0.03 ≤0.015 0.5 100 0.0 0.0 100 100 0.0 0.0
SXT All 72 0.12 .32 ≤0.015 .32 59.7 1.4 38.9 59.7 59.7 0.0 40.3
BL2 30 0.06 .32 0.03 .32 73.3 3.3 23.3 73.3 73.3 0.0 26.7
BL+ 42 0.25 .32 ≤0.015 .32 50.0 0.0 50.0 50.0 50.0 0.0 50.0
Singapore
AMCa,b All 60 1 4 0.06 16 93.3 0.0 6.7 86.7 (93.3) 86.7 (76.7)f 0.0 13.3 (23.3)f
BL2 49 1 4 0.06 16 91.8 0.0 8.2 85.7 (91.8) 85.7 0.0 14.3
BL+ 11 1 2 0.5 4 100 0.0 0.0 90.9 (100) 90.9 0.0 9.1
ampicillinc All 60 0.5 .256 0.03 .256 63.3 15.0 21.7 NA 63.3 0.0 36.7
BL2 49 0.5 2 0.03 32 77.6 18.4 4.1 NA 77.6 0.0 22.5
BL+ 11 .256 .256 64 .256 0.0 0.0 100 NA 0.0 0.0 100
azithromycind All 60 2 4 0.12 16 98.3 0.0 1.7 NA NA NA NA
BL2 49 2 4 0.12 8 100 0.0 0.0 NA NA NA NA
BL+ 11 2 4 1 16 90.9 0.0 9.1 NA NA NA NA
cefaclorb All 60 4 256 0.03 .256 75.0 (73.3)f 1.7 23.3 (25.0)f 5.0 NA NA NA
BL2 49 4 .256 0.03 .256 71.4 2.0 26.5 2.0 NA NA NA
BL+ 11 4 8 0.12 256 90.9 0.0 9.1 18.2 NA NA NA
cefuroximee,b All 60 1 8 0.06 .256 85.0 10.0 5.0 60.0 1.7 58.3 40.0
BL2 49 1 8 0.06 .256 85.7 10.2 4.1 57.1 2.0 55.1 42.9
BL+ 11 1 8 0.5 16 81.8 9.1 9.1 72.7 0.0 72.7 27.3
ciprofloxacin All 60 0.015 0.25 ≤0.015 0.5 100 0.0 0.0 100 100 0.0 0.0
BL2 49 0.015 0.25 ≤0.015 0.5 100 0.0 0.0 100 100 0.0 0.0
BL+ 11 0.015 0.25 ≤0.015 0.5 100 0.0 0.0 100 100 0.0 0.0
clarithromycind All 60 8 32 0.25 .256 83.3 8.3 8.3 NA NA NA NA
BL2 49 8 32 0.25 64 87.8 6.1 6.1 NA NA NA NA
BL+ 11 8 64 2 .256 63.6 18.2 18.2 NA NA NA NA
levofloxacin All 60 0.015 0.12 ≤0.015 0.5 100 0.0 0.0 100 100 0.0 0.0
BL2 49 0.015 0.12 ≤0.015 0.25 100 0.0 0.0 100 100 0.0 0.0
BL+ 11 0.015 0.03 ≤0.015 0.5 100 0.0 0.0 100 100 0.0 0.0
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Table 6. Continued
Susceptibility
MIC (mg/L) CLSI PK/PD EUCAST
Antimicrobial Isolate group n 50% 90% min max %S %I %R %S %S %I %R
moxifloxacin All 60 0.03 0.06 ≤0.015 2 98.3 0.0 1.7 98.3 98.3 0.0 1.7
BL2 49 0.03 0.12 ≤0.015 0.25 100 0.0 0.0 100 100 0.0 0.0
BL+ 11 0.015 0.06 ≤0.015 2 90.9 0.0 9.1 90.9 90.9 0.0 9.1
ofloxacin All 60 0.06 0.06 ≤0.015 2 100 0.0 0.0 NA 98.3 0.0 1.7
BL2 49 0.06 0.25 ≤0.015 0.5 100 0.0 0.0 NA 100 0.0 0.0
BL+ 11 0.06 0.06 0.03 2 100 0.0 0.0 NA 90.9 0.0 9.1
SXT All 60 0.12 .32 ≤0.015 .32 63.3 3.3 33.3 63.3 63.3 1.7 35.0
BL2 49 0.12 .32 ≤0.015 .32 67.4 4.1 28.6 67.4 67.4 2.0 30.6
BL+ 11 8 .32 0.03 .32 45.5 0.0 54.6 45.5 45.5 0.0 54.6
Thailand
AMCa,b All 263 1 2 0.06 16 97.7 (93.5)f 0.0 2.3 (6.5)f 90.5 (97.7) 90.5 (81.4)f 0.0 9.5 (18.6)f
BL2 167 1 2 0.06 16 98.2 0.0 1.8 93.4 (98.2) 93.4 0.0 6.6
BL+ 96 1 4 0.12 16 96.9 0.0 3.1 85.4 (96.9) 85.4 0.0 14.6
ampicillinc all 263 1 .256 0.03 .256 51.7 8.8 39.5 na 51.7 0.0 48.3
BL2 167 0.5 2 0.03 32 80.8 12.0 7.2 na 80.8 0.0 19.2
BL+ 96 .256 .256 0.5 .256 1.0 3.1 95.8 na 1.0 0.0 99.0
azithromycind all 263 2 4 0.06 16 99.6 0.0 0.4 na na na na
BL2 167 2 4 0.06 8 100 0.0 0.0 na na na na
BL+ 96 2 4 0.5 16 99.0 0.0 1.0 na na na na
cefuroximee,b all 263 0.5 2 0.03 32 96.2 (92.4)f 1.5 2.3 (6.1)f 79.5 7.2 72.4 (66.9)f 20.5 (25.9)f
BL2 167 0.5 4 0.03 16 95.2 2.4 2.4 79.0 10.1 69.1 20.8
BL+ 96 0.5 2 0.06 32 97.9 0.0 2.1 80.2 2.1 78.1 19.8
clarithromycind all 263 16 32 1 128 79.5 19.8 0.8 na na na na
BL2 167 16 32 1 128 81.4 17.4 1.2 na na na na
BL+ 96 16 32 1 32 76.0 24.0 0.0 na na na na
levofloxacin all 263 0.015 0.03 ≤0.015 .256 99.6 0.0 0.4 99.6 99.2 0.0 0.8
BL2 167 0.015 0.03 ≤0.015 .256 99.4 0.0 0.6 99.4 98.8 0.0 1.2
BL+ 96 0.015 0.03 ≤0.015 1 100 0.0 0.0 100 100 0.0 0.0
min, minimum; max, maximum; S, susceptible; I, intermediate; AMC, amoxicillin/clavulanic acid; BL2, b-lactamase negative; BL+, b-lactamase positive; NA, no breakpoint data available
(NA for azithromycin and clarithromycin by EUCAST because Etestw breakpoints in CO2 not available); SXT, trimethoprim/sulfamethoxazole.
aPK/PD susceptibility at high dose is shown in parentheses.
bIn clinical settings, isolates of BLNAR are considered resistant to amoxicillin/clavulanic acid, cefaclor and cefuroxime (see main text).
cClinically all b-lactamase-positive H. influenzae should be considered resistant.
dbioMe´rieux Etestw breakpoints for incubation in CO2.
eBreakpoints used are for cefuroxime axetil.
fClinical susceptibility to amoxicillin/clavulanic acid or cefuroxime reduced (data in parenthesis) due to corrections according to BLNAR (see main text).
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erythromycin by CLSI and EUCAST disc diffusion breakpoints
(Table 2).
Comparative susceptibility of S. pneumoniae isolates
by country
Comparative susceptibility (CLSI breakpoints) of S. pneumoniae by
country to nine antimicrobial agents is depicted in Figure 1.
Susceptibility to amoxicillin/clavulanic acid (amoxicillin) or
levofloxacin was high in all countries tested. Nevertheless,
susceptibility to amoxicillin/clavulanic acid (amoxicillin) was signifi-
cantly lower in South Korea than the other Asian countries
(P,0.05). Furthermore, susceptibility to cefuroxime, clarithromy-
cin, erythromycin and penicillin was also significantly lower in
South Korea. Susceptibility to ofloxacin in Singapore was signifi-
cantly lower than in South Korea or India.
Table 7. Distribution of H. influenzae MICs by country
Number of isolates at MIC (mg/L)
Antimicrobial na ≤0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 .32 64 128 256 .256
India
AMC 135 2 2 3 17 20 32 34 11 10 2 0 0 0 0 0 0 2
ampicillin 135 1 1 9 45 32 27 8 2 7 1 1 1 0 0 0 0 0
azithromycin 94 3 6 7 5 1 2 0 14 36 15 4 0 0 0 0 0 1
cefixime 135 24 37 45 9 3 11 2 2 0 1 0 0 0 0 0 0 1
cefpodoxime 134 5 22 41 29 8 15 4 6 1 2 0 0 0 0 0 0 1
cefuroxime 134 9 9 5 1 11 48 38 8 4 0 0 0 0 0 0 0 1
ciprofloxacin 135 21 5 10 10 16 18 23 10 5 5 2 0 10 0 0 0 0
clarithromycin 108 0 0 1 2 0 1 3 10 14 14 27 21 0 8 0 0 7
levofloxacin 135 13 14 6 9 14 26 25 8 5 5 2 0 8 0 0 0 0
ofloxacin 135 7 11 11 8 18 17 19 18 8 5 0 0 13 0 0 0 0
SXT 135 4 7 10 4 5 1 7 11 22 10 2 2 50 0 0 0 0
South Korea
AMC 72 0 0 0 0 2 4 8 14 17 12 6 5 0 0 0 0 4
ampicillin 72 0 0 0 0 5 2 5 10 5 5 2 0 0 4 1 0 33
azithromycin 72 0 0 0 0 0 1 8 40 14 5 0 1 0 1 0 0 2
cefaclor 72 0 0 0 0 0 1 1 2 13 4 6 6 0 8 1 2 28
cefuroxime 72 0 0 0 0 0 3 9 9 8 3 6 8 0 5 1 1 19
clarithromycin 72 0 0 0 0 0 0 0 0 2 8 26 27 0 5 2 0 2
levofloxacin 72 51 15 2 1 1 1 1 0 0 0 0 0 0 0 0 0 0
SXT 72 1 1 28 9 4 0 0 1 1 1 0 0 26 0 0 0 0
Singapore
AMC 60 0 0 2 2 4 9 22 13 4 3 1 0 0 0 0 0 0
ampicillin 60 0 1 0 4 7 19 7 9 0 1 0 1 0 1 0 3 7
azithromycin 60 0 0 0 1 0 0 9 32 16 1 1 0 0 0 0 0 0
cefaclor 60 0 1 0 1 0 1 4 10 20 8 1 3 0 3 1 1 6
cefuroxime 60 0 0 1 0 4 10 21 12 3 6 1 0 0 0 0 0 2
ciprofloxacin 60 49 1 0 3 5 2 0 0 0 0 0 0 0 0 0 0 0
clarithromycin 60 0 0 0 0 1 0 0 2 7 21 19 5 0 4 0 0 1
levofloxacin 60 34 19 0 4 2 1 0 0 0 0 0 0 0 0 0 0 0
moxifloxacin 60 23 24 7 2 3 0 0 1 0 0 0 0 0 0 0 0 0
ofloxacin 60 3 25 26 0 4 1 0 1 0 0 0 0 0 0 0 0 0
SXT 60 1 3 21 13 0 0 1 1 1 2 0 6 11 0 0 0 0
Thailand
AMC 263 0 0 4 7 16 72 94 45 19 3 3 0 0 0 0 0 0
ampicillin 263 0 1 4 7 44 52 28 23 11 7 18 10 0 5 1 0 52
azithromycin 263 0 0 1 1 2 21 40 108 82 7 1 0 0 0 0 0 0
cefuroxime 263 0 2 6 10 43 85 63 32 12 4 5 1 0 0 0 0 0
clarithromycin 263 0 0 0 0 0 0 4 7 28 77 93 52 0 1 1 0 0
levofloxacin 263 168 78 6 4 1 1 3 1 0 0 0 0 0 0 0 0 1
AMC, amoxicillin/clavulanic acid (2:1); SXT, trimethoprim/sulfamethoxazole (1:19).
aNot all isolates were tested.
SOAR: Thailand, India, South Korea and Singapore 2012–14
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Prevalence of antibiotic susceptibility among PSSP, PISPand
PRSP isolates (based on CLSI penicillin oral breakpoints)
Utilizing the CLSI (oral) breakpoints, the relationship between sus-
ceptibility to penicillin and susceptibility to other antimicrobial
agents was assessed for the pooled set of 570 S. pneumoniae
strains from the four countries (Figure 2).
Among 265 PSSP, 99.6% were susceptible to amoxicillin/clavu-
lanic acid (amoxicillin) or cefuroxime, 84%–88% were susceptible
to macrolides and 97.0% to levofloxacin.
The 215 PISP were 98.1% susceptible to amoxicillin/clavulanic
acid (amoxicillin) and 92.1% were susceptible to levofloxacin.
Susceptibility to cefuroxime was 64.0% and macrolide susceptibil-
ity ranged from 19% to 27%.
For the 90 PRSP, 57.8% were susceptible to amoxicillin/clavula-
nic acid (amoxicillin) and 80% susceptible to levofloxacin.
Macrolide susceptibility ranged from 1% to 9% and cefuroxime
susceptibility was 2.2%.
Susceptibility to all agents tested was significantly lower
in PRSP compared with PISP and PISP compared with PSSP
Table 8. MIC and susceptibility results for M. catarrhalis isolates by country
Susceptibility
MIC (mg/L) CLSI PK/PD EUCAST
Antimicrobial na 50% 90% min max %S %I %R %S %S %I %R
India
AMCb 61 0.25 2 0.03 16 98.4 0.0 1.6 93.4 (98.4) 80.3 0.0 19.7
azithromycin 61 0.5 8 ≤0.015 .256 NA NA NA NA NA NA NA
cefixime 37 0.5 0.5 0.06 1 NA NA NA 100 97.3 2.7 0.0
cefpodoxime 61 1 2 0.12 8 NA NA NA 45.9 NA NA NA
cefuroximec 59 2 16 0.25 64 81.4 6.8 11.9 23.7 0.0 81.4 18.6
ciprofloxacin 61 1 8 ≤0.015 .32 67.2 0.0 32.8 67.2 34.4 0.0 65.6
clarithromycin 49 0.5 8 ≤0.015 64 NA NA NA NA NA NA NA
levofloxacin 61 1 8 0.03 .32 80.3 0.0 19.7 80.3 57.4 0.0 42.6
South Korea
AMCb 18 0.12 0.25 ≤0.015 0.25 100 0.0 0.0 100 (100) 100 0.0 0.0
azithromycin 4 0.12 .256 0.06 .256 NA NA NA NA NA NA NA
cefaclor 18 0.5 1 ≤0.015 1 100 0.0 0.0 50.0 NA NA NA
cefuroximec 18 1 2 0.03 2 100 0.0 0.0 50.0 5.6 94.4 0.0
ciprofloxacin 18 0.06 0.12 0.03 0.12 100 0.0 0.0 100 100 0.0 0.0
clarithromycin 18 0.5 2 0.12 .256 NA NA NA NA NA NA NA
levofloxacin 18 0.03 0.06 0.03 0.06 100 0.0 0.0 100 100 0.0 0.0
Singapore
AMCb 15 0.06 0.25 ≤0.015 0.5 100 0.0 0.0 100 (100) 100 0.0 0.0
azithromycin 20 0.12 0.25 0.12 0.5 NA NA NA NA NA NA NA
cefaclor 20 2 4 1 4 100 0.0 0.0 0.0 NA NA NA
cefuroximec 14 1 2 0.12 4 100 0.0 0.0 57.1 7.1 92.9 0
ciprofloxacin 20 0.06 0.06 0.03 0.5 100 0.0 0.0 100 100 0.0 0.0
clarithromycin 20 0.25 0.25 0.03 0.5 NA NA NA NA NA NA NA
levofloxacin 20 0.06 0.06 0.03 0.06 100 0.0 0.0 100 100 0.0 0.0
moxifloxacin 20 0.06 0.06 0.06 0.06 NA NA NA 100 100 0.0 0.0
Thailand
AMCb 49 0.25 0.5 0.03 0.5 100 0.0 0.0 100 (100) 100 0.0 0.0
azithromycin 49 0.25 1 ≤0.015 .256 NA NA NA NA NA NA NA
cefuroximec 49 1 2 0.06 4 100 0.0 0.0 63.3 2.0 98.0 0.0
clarithromycin 49 0.25 1 0.03 .256 NA NA NA NA NA NA NA
levofloxacin 49 0.06 0.12 0.03 .32 98.0 0.0 2.0 98.0 98.0 0.0 2.0
min, minimum; max, maximum; S, susceptible; I, intermediate; AMC, amoxicillin/clavulanic acid; NA, no breakpoint data available (NA for azithromycin
and clarithromycin by CLSI, PK/PD or EUCAST because Etestw breakpoints in CO2 not available).
aNot all isolates were tested.
bPK/PD susceptibility at high dose is shown in parentheses.
cBreakpoints used are for cefuroxime axetil.
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(P,0.05) with the exception of amoxicillin/clavulanic acid (amoxi-
cillin), where there was no statistically significant difference in
activity against PSSP and PISP (P¼0.111).
CLSI guidelines indicate that isolates susceptible to penicillin G
(MIC ≤0.06 mg/L) can be reported as susceptible to amoxicillin,
amoxicillin/clavulanic acid, cefaclor and cefuroxime. Data from
this study confirmed this, as all penicillin-susceptible S. pneumo-
niae were also susceptible to cefaclor and all isolates except one
were also susceptible to amoxicillin/clavulanic acid (amoxicillin)
and cefuroxime. However, the reverse was not always found,
with 86.2% and 45.7% of penicillin non-susceptible isolates
susceptible to amoxicillin/clavulanic acid (amoxicillin) and cefur-
oxime, respectively. However, only 5.7% of penicillin-susceptible
S. pneumoniae were cefaclor susceptible. A similar ‘expert rule’
is provided by EUCAST but for penicillins only, i.e. amoxicillin/
clavulanic acid (amoxicillin) in this study. However, unlike CLSI,
individual breakpoints are not provided by EUCAST for amoxicil-
lin/clavulanic acid to make this comparison.
S. pyogenes susceptibility
Only India provided isolates of S. pyogenes. Summary MIC and sus-
ceptibility data and MIC distributions are shown in Tables 4 and 5.
All isolates were fully susceptible to penicillin and therefore,
according to CLSI and EUCAST guidelines, may be considered sus-
ceptible to amoxicillin/clavulanic acid (amoxicillin) and cephalos-
porins. However, susceptibility to levofloxacin was 79.5% by CLSI
and 55.1% by EUCAST and ofloxacin susceptibility (CLSI only) was
52.6%. Trimethoprim/sulfamethoxazole breakpoints are only
available by EUCAST and PK/PD, which showed that susceptibility
was low, at 33.3%. Erythromycin susceptibility was the lowest of
all, at 21.8%–23.7% (Table 4).
Table 9. Distribution of M. catarrhalis MICs by country
Number of isolates at MIC (mg/L)
Antimicrobial na ≤0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 .32 64 .256
India
AMC 61 0 4 5 18 7 7 8 8 3 0 1 0 0 0 0
azithromycin 61 4 3 0 9 11 9 7 7 4 3 1 0 0 0 3
cefixime 37 0 0 5 6 7 18 1 0 0 0 0 0 0 0 0
cefpodoxime 61 0 0 0 4 8 16 15 14 2 2 0 0 0 0 0
cefuroxime 59 0 0 0 0 1 2 11 24 10 4 5 1 0 1 0
ciprofloxacin 61 1 0 9 1 1 9 20 9 0 7 1 0 3 0 0
clarithromycin 49 2 1 1 0 7 21 4 0 5 4 3 0 0 1 0
levofloxacin 61 0 2 8 2 1 5 17 14 1 7 1 0 3 0 0
South Korea
AMC 18 2 3 1 3 9 0 0 0 0 0 0 0 0 0 0
azithromycin 4 0 0 1 2 0 0 0 0 0 0 0 0 0 0 1
cefaclor 18 1 0 1 0 2 5 9 0 0 0 0 0 0 0 0
cefuroxime 18 0 1 0 0 3 1 4 9 0 0 0 0 0 0 0
ciprofloxacin 18 0 4 12 2 0 0 0 0 0 0 0 0 0 0 0
clarithromycin 18 0 0 0 1 5 9 1 1 0 0 0 0 0 0 1
levofloxacin 18 0 15 3 0 0 0 0 0 0 0 0 0 0 0 0
Singapore
AMC 15 1 3 4 1 5 1 0 0 0 0 0 0 0 0 0
azithromycin 20 0 0 0 13 5 2 0 0 0 0 0 0 0 0 0
cefaclor 20 0 0 0 0 0 0 2 14 4 0 0 0 0 0 0
cefuroxime 14 0 0 0 1 0 1 6 5 1 0 0 0 0 0 0
ciprofloxacin 20 0 4 15 0 0 1 0 0 0 0 0 0 0 0 0
clarithromycin 20 0 1 0 6 11 2 0 0 0 0 0 0 0 0 0
levofloxacin 20 0 2 18 0 0 0 0 0 0 0 0 0 0 0 0
moxifloxacin 20 0 0 20 0 0 0 0 0 0 0 0 0 0 0 0
Thailand
AMC 49 0 2 3 10 28 6 0 0 0 0 0 0 0 0 0
azithromycin 49 4 7 4 5 9 15 3 0 0 0 0 0 0 0 2
cefuroxime 49 0 0 1 0 2 6 22 17 1 0 0 0 0 0 0
clarithromycin 49 0 5 4 13 16 6 3 0 0 1 0 0 0 0 1
levofloxacin 49 0 3 40 3 0 0 2 0 0 0 0 0 1 0 0
AMC, amoxicillin/clavulanic acid.
aNot all isolates were tested.
SOAR: Thailand, India, South Korea and Singapore 2012–14
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H. influenzae susceptibility in individual countries
Summary MIC and susceptibility data for all H. influenzae isolates
are shown in Table 6 and the complete MIC distribution data in
Table 7.
India
For all H. influenzae (n¼135), susceptibility to amoxicillin/clavula-
nic acid by CLSI and PK/PD high-dose criteria was 97.0%, and
89.6% by EUCAST or PK/PD low-dose criteria. Susceptibility to
ampicillin was 91.1% by CLSI and EUCAST criteria, which reflects
the prevalence of b-lactamase-positive isolates (n¼11, 8.1%).
None was b-lactamase negative and ampicillin resistant
(BLNAR) according to the CLSI definition (ampicillin MIC ≥4 mg/
L), but one isolate was BLNAR according to the EUCAST definition
(ampicillin MIC ≥2 mg/L).
Using CLSI breakpoints, susceptibility to cephalosporins was
high, at 97%–99%. However, using EUCAST breakpoints, rates of
susceptibility were lower for cefixime (85.2%) and cefpodoxime
(78.4%) and much lower for cefuroxime (17.9%), therefore show-
ing considerable difference in cephalosporin susceptibility
depending on the breakpoints used (Table 6).
Azithromycin susceptibility was high, at 94.7%, but clarithro-
mycin was much lower, at 66.7% (CLSI breakpoints in CO2).
As would be expected, none of the b-lactamase-positive iso-
lates was susceptible to ampicillin, but also none was susceptible
to trimethoprim/sulfamethoxazole. Among the b-lactamase-
positive isolates, 27.3% were resistant to amoxicillin/clavulanic
acid by CLSI breakpoints (36.4% by EUCAST breakpoints)
(Table 6).
South Korea
Of the 72 H. influenzae isolates from South Korea, 42 (58.3%) were
b-lactamase positive. In addition, 13 isolates (18.1%) were BLNAR
according to CLSI definition (ampicillin MIC ≥4 mg/L) and 22 iso-
lates (30.6%) were BLNAR according to the EUCAST definition
(ampicillin MIC ≥2 mg/L). As a consequence, ampicillin activity
was very low (16.7% susceptibility by CLSI and EUCAST criteria).
Susceptibility to amoxicillin/clavulanic acid in vitro was 62.5% by
CLSI or high-dose PK/PD breakpoints and 38.9% by EUCASTor low-
dose PK/PD pharmacokinetics. However, taking BLNAR (consid-
ered to be resistant) into account, the clinical susceptibility was
reduced further to 56.9% and 31.9%, respectively.
Susceptibility to cefuroxime and cefaclor was also low by CLSI,
at 40.3% and 29.2%, respectively. None of the isolates was sus-
ceptible to cefuroxime by EUCAST breakpoints and 16.7% were
susceptible by PK/PD breakpoints. Cefaclor susceptibility by PK/
PD was 1.4% (Table 6).
Azithromycin susceptibility was high, at 94.4%, but much lower
for clarithromycin, at 50% (CLSI breakpoints in CO2) (Table 6).
Singapore
Eleven of the 60 isolates (18.3%) were b-lactamase positive and 2
(3.3%) were BLNAR according to the CLSI definition (ampicillin MIC
≥4 mg/L) and 11 isolates (18.3%) were BLNAR according to the
EUCASTdefinition (ampicillin MIC≥2 mg/L). Ampicillin susceptibil-
ity was 63.3% by both CLSI and EUCAST criteria. Susceptibility to
amoxicillin/clavulanic acid was 93.3% by CLSI and PK/PD high-
dose breakpoints and 86.7% by EUCAST and low-dose PK/PD
breakpoints. Using CLSI breakpoints, the rates of susceptibility to
cefuroxime and cefaclor were reduced to 85% and 75%, respect-
ively, but were even lower using PK/PD or EUCAST breakpoints:
1.7% susceptible to cefuroxime by EUCAST and 5.0% susceptible
to cefaclor by PK/PD breakpoints (Table 6).
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Figure 1. Percentage susceptibility rates (with 95% confidence intervals)
for antimicrobials against S. pneumoniae by country according to CLSI
breakpoints. Note that only disc diffusion test results are shown for
erythromycin. aSample sizes in India were: azithromycin and clarithromycin,
n¼199; cefuroxime and erythromycin, n¼218. bOfloxacin and trimethoprim/
sulfamethoxazole were not tested in Thailand. AMC, amoxicillin/clavulanic
acid; SXT, trimethoprim/sulfamethoxazole.
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Figure 2. Percentage susceptibility rates (with 95% confidence intervals)
for antimicrobials according to CLSI breakpoints against PSSP, PISP and
PRSP, combining India, South Korea, Singapore and Thailand. Penicillin
susceptibility category is based on oral penicillin CLSI breakpoints. Sample
sizes varied by antimicrobial agents and are shown at the bottom. Only
antimicrobials that were tested in each country are included. Only results
for erythromycin by disc diffusion are included. aSample sizes for PSSP
were: azithromycin and clarithromycin, n¼261; erythromycin, n¼264.
bSample sizes for PISP were: azithromycin and clarithromycin, n¼204;
cefuroxime, n¼214. cSample sizes for PRSP were: azithromycin and
clarithromycin, n¼85. AMC, amoxicillin/clavulanic acid.
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Azithromycin susceptibility was high (98.3%), as was suscepti-
bility to clarithromycin (83.3%) by CLSI breakpoints in CO2 (Table 6).
Thailand
Ninety-six out of 263 isolates were b-lactamase positive (36.5%).
Twelve (4.6%) were BLNAR according to the CLSI definition (ampi-
cillin MIC ≥4 mg/L) and 32 (12.2%) were BLNAR according to the
EUCAST definition (ampicillin MIC ≥2 mg/L). Therefore, ampicillin
susceptibility was low, at 51.7%, whereas 97.7% were susceptible
to amoxicillin/clavulanic acid by CLSI and high-dose PK/PD break-
points or 90.5% by EUCAST and low-dose PK/PD breakpoints.
Cefuroxime susceptibility was high with CLSI breakpoints
(96.2%) but 79.5% by PK/PD and 7.2% by EUCAST (Table 6).
Virtually all isolates were susceptible to azithromycin (99.6%)
but only 79.5% were susceptible to clarithromycin (CLSI break-
points in CO2). More than 99% of isolates were susceptible to
levofloxacin by all three breakpoints (Table 6).
Comparative susceptibility of H. influenzae isolates by
country
Some clear differences between the countries were apparent: sus-
ceptibility to amoxicillin/clavulanic acid, ampicillin, cefuroxime
and clarithromycin were significantly lower in South Korea than
in other countries. In addition, susceptibility to levofloxacin and
trimethoprim/sulfamethoxazole was significantly lower in India
(data not shown).
M. catarrhalis susceptibility in individual countries
Summary MIC and susceptibility data for all M. catarrhalis isolates
are shown in Table 8 and the complete MIC distribution data are in
Table 9.
For South Korea, Singapore and Thailand, 100% susceptibility
was observed according to CLSI breakpoints for all antimicrobial
agents tested (except 98.0% for levofloxacin in Thailand).
Amoxicillin/clavulanic acid and fluoroquinolone susceptibility
was also 100% (except 98.0% for levofloxacin in Thailand) for
both PK/PD and EUCAST breakpoints (Table 8). As noted previously
for other bacterial pathogens, susceptibility to cefaclor and cefu-
roxime was significantly lower according to EUCAST and/or PK/PD
breakpoints.
Isolates of M. catarrhalis from India were less susceptible
to antimicrobial agents, but these were still 98.4% susceptible
to amoxicillin/clavulanic acid by CLSI or PK/PD high-dose break-
points and 93.4% by PK/PD low-dose breakpoints. Amoxicillin/
clavulanic acid susceptibility by EUCAST breakpoints was 80.3%.
Susceptibility to cefuroxime was 81.4% by CLSI breakpoints,
23.7% by PK/PD and 0% by EUCAST. Cefpodoxime has PK/PD
breakpoints that indicated 45.9% susceptibility. Levofloxacin sus-
ceptibility was 80.3% by CLSI or PK/PD and 57.4% by EUCAST.
Lower susceptibility was observed for ciprofloxacin, at 67.2%
and 34.4%, respectively (Table 8).
Age group analysis
Using CLSI breakpoints, susceptibility to tested antimicrobial
agents was compared across age groups in each of the countries
(data not shown). Insufficient isolates from the individual age
groups were obtained from India for H. influenzae or from all
countries for M. catarrhalis to allow an analysis to be performed.
Generally, there was no significant difference when comparing
antimicrobial agent susceptibility between age groups for each
country for S. pneumoniae, S. pyogenes or H. influenzae. In the
few cases where a significant difference in susceptibility by age
group was observed (P,0.05) there tended to be lower suscepti-
bility in paediatric patients compared with adults and/or the eld-
erly: amoxicillin/clavulanic acid versus S. pneumoniae in South
Korea—paediatric (57.1%) versus adult (92.0%); trimethoprim/
sulfamethoxazole versus S. pneumoniae in South Korea—paediat-
ric (7.1%) versus adult (48.0%) or elderly (52.2%); penicillin versus
S. pneumoniae in Thailand—paediatric (32.4%) versus elderly
(57.3%); and ampicillin versus H. influenzae in South Korea—
paediatric (0%) versus adult (20.0%) or elderly (27.3%). In one
case there was a difference between adults and the elderly:
ofloxacin versus S. pneumoniae in India—adults (73.4%) versus
elderly (93.9%).
Discussion
SOAR is an ongoing surveillance study (which began in 2002) of
key respiratory pathogens in various parts of the world. The data
presented here concern the susceptibility of S. pneumoniae,
S. pyogenes, H. influenzae and M. catarrhalis isolated during the
2012–14 period in India, South Korea, Singapore and Thailand.
Antimicrobial agent resistance in respiratory pathogens is
considered to be a worldwide problem, although susceptibility
can differ widely among countries. The SOAR study has previously
evaluated S. pneumoniae, H. influenzae and M. catarrhalis from
Singapore (2009–11) and S. pneumoniae from Thailand (2007–
09).19,20 It would appear that antibiotic susceptibility in S. pneumo-
niae and M. catarrhalis from Singapore has not varied significantly
between 2009–11 and the current study period (2012–14) (data
not shown). For H. influenzae in Singapore, ampicillin susceptibility
reduced from 72% in 2009–11 to 63.3% in 2012–14, but this is not
a statistically significant change (P¼0.252). Similar insignificant
changes in susceptibility occurred for other antibiotics against
H. influenzae in Singapore, except for cefuroxime, where susceptibil-
ity reduced from 99% in 2009–11 to 85% in 2012–14, which is
statistically significant (P¼0.0004). In the Thailand 2007–09
study, the testing was done in various phases, which makes it dif-
ficult to make direct comparisons for most antibiotics.20 However,
macrolide susceptibility based on erythromycin disc testing showed
a reduction in susceptibility from 60.4% in 2007–09 to 51.9%
in 2012–14, which is just marginally short of being significant
(P¼0.063).
Overall, antimicrobial resistance was not a major issue for
S. pyogenes (all isolates from India), which were all fully sus-
ceptible to penicillin and, by association, other b-lactam
agents such as cephalosporins and amoxicillin/clavulanic acid.
Nevertheless, erythromycin susceptibility was very low, at around
20%, thereby reducing the clinical utility of macrolides for respira-
tory infections caused by S. pyogenes in India.
Antimicrobial agent susceptibility was very high in M. catarrha-
lis from South Korea, Singapore and Thailand based on CLSI break-
points. Based on EUCAST and PK/PD breakpoints, prevalence
of resistance to cefuroxime and cefaclor was high. Following
EUCAST guidelines, amoxicillin/clavulanic acid or fluoroquinolones
would be the only viable treatment option. However, it is import-
ant to note that we were unable to assess the activity of
SOAR: Thailand, India, South Korea and Singapore 2012–14
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macrolides against M. catarrhalis due to a lack of breakpoints in
the presence of CO2. M. catarrhalis from India showed reduced
susceptibility to fluoroquinolones and cefuroxime.
Antimicrobial susceptibility in H. influenzae was generally high
in India, Singapore and Thailand, with significantly lower antibiotic
susceptibility in South Korea for all antimicrobial agents, except
for azithromycin, levofloxacin and trimethoprim/sulfamethoxa-
zole. Trimethoprim/sulfamethoxazole susceptibility was amongst
the lowest in each country where it was tested, but was signifi-
cantly lower in India than elsewhere. This may relate to reported
extensive use of trimethoprim/sulfamethoxazole in India.21
Levofloxacin susceptibility was also significantly lower in India
than other countries, which complements the susceptibility data
for M. catarrhalis from India. The prevalence of b-lactamase varied
from country to country and was highest in South Korea (58.3%)
and lowest in India (8.1%). However, amoxicillin/clavulanic acid sus-
ceptibility was .90% in all countries except South Korea (62.5%).
Low antimicrobial agent susceptibility is a major problem in H. influ-
enzae from South Korea, as found previously,14 and the data from
this current study suggest that only azithromycin and levofloxacin
are treatment options for H. influenzae from this country.
For S. pneumoniae, susceptibility to macrolides, trimethoprim/
sulfamethoxazole and penicillin was very low in each of the four
Asian countries, as found in previous publications.11 – 13 Overall,
only amoxicillin/clavulanic acid and levofloxacin had .80% sus-
ceptibility in all four countries. As observed with H. influenzae,
low antimicrobial agent susceptibility is a particular problem
in South Korea. Penicillin non-susceptibility is also a problem in
this region of the world because of associated cross-resistance
to macrolides and also, but to a lesser extent, to amoxicillin/
clavulanic acid (amoxicillin). Data from this study indicate that
only levofloxacin has good activity against penicillin-resistant
pneumococci.
The data from this study confirm that isolates of S. pneumo-
niae susceptible to penicillin G are also susceptible to other
penicillins as inferred by CLSI and EUCAST guidelines and cephalos-
porins as inferred by CLSI guidelines. Interestingly, the data from
this study found the reverse was not always correct using CLSI
breakpoints; i.e. most penicillin-non-susceptible S. pneumoniae
were susceptible to amoxicillin/clavulanic acid (amoxicillin) and
cefuroxime. Therefore, either these b-lactam agent breakpoints
are not correct or the CLSI cross-resistance statement within the
b-lactam class is not correct. This warrants further investigation.
Our analysis would indicate that generally there is little differ-
ence in antimicrobial agent susceptibility between isolates from
varying patient age groups. Where differences did occur, generally
the susceptibility of paediatric isolates was lower than that of
adults or the elderly. A global demographic analysis study found
similar results for penicillin and erythromycin susceptibility in
infants compared with both adults and the elderly,22 and SOAR
data from Turkey also found this to be true for penicillin but not
macrolides.23 Interestingly, within the same geographical region,
SOAR Vietnam paediatric isolates were less susceptible to most
antibiotics than isolates from the elderly, but there was no differ-
ence compared with adults (except for azithromycin).24
In this analysis we measured susceptibility by three breakpoint
criteria. In general these produced quite similar results. However,
there were notable exceptions. The first of these was considerably
lower cefaclor and ofloxacin susceptibility by EUCAST compared
with CLSI with S. pneumoniae. To a lesser extent this was also
the case for cefuroxime and cefpodoxime. Similarly, in H. influen-
zae cefuroxime and ciprofloxacin susceptibility was considerably
lower with EUCAST than with CLSI. This has been noted else-
where25 and in other SOAR publications.22,23 As has been stated
previously, considerable harmonization of breakpoints is neces-
sary to avoid confusion and potentially poor therapeutic
decisions.
In summary, we have analysed antibiotic susceptibility in
community-acquired respiratory pathogens. There are quite
large country-specific differences in antibiotic susceptibility even
within the same region, with overall antibiotic resistance being
the highest in S. pneumoniae and isolates from South Korea.
These data reinforce the need for regular antibiotic resistance sur-
veillance to track changes in susceptibility over time.
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